BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 8492769)

  • 1. Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry.
    Langmuir VK; Fowler JF; Knox SJ; Wessels BW; Sutherland RM; Wong JY
    Med Phys; 1993; 20(2 Pt 2):601-10. PubMed ID: 8492769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation.
    Knox SJ; Goris ML; Wessels BW
    Radiother Oncol; 1992 Feb; 23(2):111-7. PubMed ID: 1546186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
    Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental radioimmunotherapy.
    Buchsbaum DJ; Langmuir VK; Wessels BW
    Med Phys; 1993; 20(2 Pt 2):551-67. PubMed ID: 8492764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationales, evidence, and design considerations for fractionated radioimmunotherapy.
    DeNardo GL; Schlom J; Buchsbaum DJ; Meredith RF; O'Donoghue JA; Sgouros G; Humm JL; DeNardo SJ
    Cancer; 2002 Feb; 94(4 Suppl):1332-48. PubMed ID: 11877764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
    Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
    J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles.
    Leichner PK; Kwok CS
    Med Phys; 1993; 20(2 Pt 2):529-34. PubMed ID: 8492761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microdosimetric concepts in radioimmunotherapy.
    Humm JL; Roeske JC; Fisher DR; Chen GT
    Med Phys; 1993; 20(2 Pt 2):535-41. PubMed ID: 8492762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined low dose radio- and radioimmunotherapy of experimental HeLa Hep 2 tumours.
    Eriksson D; Joniani HM; Sheikholvaezin A; Löfroth PO; Johansson L; Riklund Ahlström K; Stigbrand T
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):895-906. PubMed ID: 12721768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts.
    Sautter-Bihl ML; Wessely R; Bihl H
    Strahlenther Onkol; 1993 Oct; 169(10):595-600. PubMed ID: 8235984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of studies on experimental radioimmunotherapy.
    Knox SJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5832s-5836s. PubMed ID: 7493355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of different cell cluster models on the radiobiological output for (211)At-radioimmunotherapy.
    Lin H; Jing J; Xu Y
    Cancer Biother Radiopharm; 2011 Feb; 26(1):85-95. PubMed ID: 21355780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiobiological aspects of low dose rates in radioimmunotherapy.
    Fowler JF
    Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1261-9. PubMed ID: 2347734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
    Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
    Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing.
    DeNardo GL; Juweid ME; White CA; Wiseman GA; DeNardo SJ
    Crit Rev Oncol Hematol; 2001; 39(1-2):203-18. PubMed ID: 11418317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.
    Shimoni A; Zwas ST
    Semin Nucl Med; 2016 Mar; 46(2):119-25. PubMed ID: 26897716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of radiobiological concepts in radionuclide therapy of cancer.
    Kumar C; Shetake N; Desai S; Kumar A; Samuel G; Pandey BN
    Int J Radiat Biol; 2016; 92(4):173-86. PubMed ID: 26917443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetry of solid tumors.
    Meredith RF; Johnson TK; Plott G; Macey DJ; Vessella RL; Wilson LA; Breitz HB; Williams LE
    Med Phys; 1993; 20(2 Pt 2):583-92. PubMed ID: 8492767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.